Chandler Park, MD, MSc, FACP

medical oncologist, Norton Healthcare

Articles

ASCO 2025: Top Data Highlights from 6/3

June 3rd 2025

MedNews Week host Yan Leyfman, MD, speaks with 2 key opinion leaders at ASCO 2025 about the top data highlights of the day.

ASCO 2025: Top Data Highlights from 6/2

June 3rd 2025

MedNews Week hosts speak with 8 key opinion leaders at ASCO 2025 about the top data highlights of the day.

ASCO 2025: Top Data Highlights from 6/1

June 2nd 2025

MedNews Week hosts speak with 5 key opinion leaders at ASCO 2025 about the top data highlights of the day.

Evolving Molecular Profiling and Liquid Biopsy Practices Guide First-Line CRC Therapy Decisions: With Chandler Park, MD; and Midhun Malla, MD

May 29th 2025

Park and Malla discuss evolving approaches to colorectal cancer (CRC) management, with a focus on ctDNA, adjuvant therapy decision-making, and molecular profiling in metastatic disease.

Social Media Expands Access to Practical Public Health Education: With Chandler Park, MD; and Paul Hanona, MD

May 26th 2025

Drs Park and Hanona discuss the ways that public health content creation offers practical advice about a variety of topics but may also spark debate.

Motivation and Consistency Are Key to Building a Successful Oncology Educational Platform: With Chandler Park, MD; and Paul Hanona, MD

April 21st 2025

In this episode, Drs Park and Hanona give advice to up-and-coming oncology content creators.

Social Media Unlocks New Avenues for Expanding Access to Oncology Education: With Chandler Park, MD; and Paul Hanona, MD

April 16th 2025

Drs Park and Hanona discuss the role of social media in educating patients and oncologists about treatment advances and novel cancer screening methods.

Bladder-Sparing Strategies and ctDNA-Guided Strategies Take Center Stage in MIBC: With Chandler Park, MD; and Vadim Koshkin, MD

April 14th 2025

Drs Park and Koshkin explore the clinical implications of the phase 3 NIAGARA trial for patients with resectable bladder cancer.

Innovative Research Raises Questions About the Role of ADCs in Bladder Cancer: With Chandler Park, MD; and Vadim Koshkin, MD

April 9th 2025

Drs Park and Koshkin discuss sequencing antibody-drug conjugates for bladder cancer and the potential future role of sacituzimab govitecan in this disease.

Comprehensive First-Line Bladder Cancer Treatment Begins With Careful Patient Selection: With Chandler Park, MD

April 3rd 2025

Dr Park discusses the core regimens in the current frontline bladder cancer treatment paradigm and ways that this paradigm is expected to evolve.

ADC-Based Combinations Gain Momentum in Bladder Cancer Management: With Chandler Park, MD; and Vadim Koshkin, MD

April 3rd 2025

Drs Park and Koshkin discuss the benefits of enfortumab vedotin in bladder cancer and the potential for more ADCs to join the treatment paradigm.

Dr Park on Individualized First-Line Bladder Cancer Management Options

March 27th 2025

Chandler Park, MD, discusses key factors that facilitate decisions between the available frontline treatment regimens for patients with bladder cancer.

Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc

March 26th 2025

Drs Park and LaCasce discuss advancements in Hodgkin and non-Hodgkin lymphoma management, including efforts to reduce long-term toxicity.

Perioperative Durvalumab Improves Survival in MIBC: Navigating the NIAGARA Trial Findings With: Chandler Park, MD; and Petros Grivas, MD, PhD

March 12th 2025

Drs. Grivas and Park discuss developments in bladder cancer research, including the potential of HER2-targeted therapies and PD-1/PD-L1 inhibitors in the neoadjuvant setting.

Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD

February 26th 2025

Drs Park, Grivas, and Raychaudhuri discuss a trial of neoadjuvant aMVAC plus pembrolizumab in patients with non-urothelial muscle-invasive bladder cancer.

MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD

January 15th 2025

Drs Park and Leyfman discuss their commitment to advancing global medical education, mentoring future leaders, and bridging gaps in access to accurate health care information.

Dr Park on Patient and Disease Factors that Affect Treatment Decisions for mHSPC

January 13th 2025

Chandler Park, MD, FACP, discusses patient characteristics, disease factors, and drug mechanisms of action that influence treatment decisions in mHSPC.

Clinical Practice Insights Reveal the Complexity of Lymphoma Subtypes and Advances in First-Line Treatments: With Chandler Park, MD; and Joshua Brody, MD

January 8th 2025

Chandler Park, MD and Joshua Brody, MD discusses treatment challenges posed by the diverse spectrum of lymphomas, ranging from indolent subtypes, to aggressive diseases like Burkitt lymphoma.

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

January 1st 2025

Drs Park and Curigliano discuss the DESTINY-Breast06 trial of T-DXd in patients with HER2-low or -ultralow, HR–positive, metastatic breast cancer.

Wrapping up the Pivotal Highlights From SABCS 2024 With Drs Bora Lim and Stephanie Graff

December 13th 2024

Bora Lim, MD, of The University of Texas MD Anderson Cancer, and Stephanie Graff, MD, of Brown University Health, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.